Whether it is to purify, cleanse, accelerate healing or close the wound, the LINK Medical Technologies range from URGO has a product to suit.
The next generation for chronic and reoccurring wounds is URGOSTART.® Incorporating Lipido-Colloid Technology (LCT), along with its unique accelerating compound NOSF to rebalance wound equilibrium and neutralise proteases, URGOSTART® has been clinically shown to promote faster healing therefore saving nursing time and to improve patient's quality of life with less pain and less trauma.
LINK Medical Technologies and Urgo Medical in partnership are committed to supporting families affected by Epidermolysis-Bullosa (EB). More information on EB can be found on: www.epidermolysis-bullosa.com
LINK Healthcare | Medical & Pharmaceutical Products
LINK Healthcare is a privately owned Australian-based specialist Pharmaceutical and Medical Technology business. LINK's mission is to strive for excellence in the marketing of a vitally important and ...